Effects of transcranial magnetic stimulation on anhedonia in treatment resistant major depressive disorder

Brain Behav. 2021 Sep;11(9):e2329. doi: 10.1002/brb3.2329. Epub 2021 Aug 28.

Abstract

Background: Anhedonia is one of the defining features of depression but it remains difficult to target and treat. Transcranial magnetic stimulation (TMS) is a proven treatment for depression, but its effects on anhedonia and whether anhedonia can be used as a predictive biomarker of response is not well known.

Methods: Snaith-Hamilton Pleasure Scale was administered to patients with depression before and after a standard course of TMS in a naturalistic outpatient setting.

Results: 144 patients were analyzed. There was an overall significant improvement in anhedonia from pre- to post-treatment (7.69 ± 3.88 vs. 2.96 ± 3.45; p < .001). Significant correlations between improvements in anhedonia and other depressive symptoms were present (r = 0.55, p < .001). Logistic regression revealed that baseline anhedonia severity was not a significant predictor of clinical outcome.

Conclusion: This is the first large, naturalistic study examining the effects of standard, non-research TMS on anhedonia. Among depressed patients, TMS resulted in significant improvements in anhedonia. Patients with severe baseline anhedonia had an equal chance of achieving clinical response/remission. Patients with anhedonia should not be excluded from treatment if they are safe for outpatient care and otherwise appropriate candidates for treatment.

Keywords: anhedonia; depression; naturalistic; transcranial magnetic stimulation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anhedonia
  • Biomarkers
  • Depressive Disorder, Major* / therapy
  • Depressive Disorder, Treatment-Resistant* / therapy
  • Humans
  • Transcranial Magnetic Stimulation
  • Treatment Outcome

Substances

  • Biomarkers